AC Immune (ACIU) Insider June Carl Howard Buys 16,568 Shares

June Carl Howard Adds to AC Immune SA Stake

June Carl Howard acquired 16,568 shares of AC Immune SA (NasdaqGM: ACIU) on June 11, 2026. This transaction added to an active period of insider activity at the clinical-stage biotechnology firm, following prior coverage of executive and board purchases on the exact same date. While individual transaction values for this round were reported without listed share prices or monetary totals, the clustered buying brought multiple key stakeholders further into the equity.

Insider Buying and Selling at AC Immune SA

This purchase did not happen in isolation, as several other insiders stepped up to increase their holdings on June 11, 2026. Interim CEO Martin Zuegel acquired 77,778 shares. At the same time, Renee Aguiar-Lucander picked up 38,889 shares, Twyman Roy Ervin added 38,889 shares, and Monika Buetler grabbed 17,751 shares. These coordinated moves show multiple leaders adding to their positions on the same day.

Stock Valuation and Trading Levels

The stock recently changed hands at $2.35 per share on Monday, sitting well below its 50-day moving average of $2.53 and its 200-day moving average of $2.82. The equity has moved between a 52-week low of $2.10 and a peak of $4.00. With a market capitalization of roughly $263.98 million and a forward PE ratio of 4.41, the valuation reflects the current market pricing for its pipeline.

Analysts Set New Price Targets

Wall Street firms tracking the company continue to hold an optimistic view of its long-term potential. On September 23, 2026, BTIG reiterated its Buy rating on the stock with an $8.00 price target, following similar reiterations on August 20, 2026, and August 5, 2026. Across the broader community, four analysts provide coverage, generating a consensus target mean price of $8.40 with individual targets spanning from a low of $5.27 up to a high of $11.68.

Inside the Biotechnology Pipeline

Headquartered in Lausanne, Switzerland, AC Immune SA discovers and develops medicines and diagnostic products to prevent and treat neurodegenerative diseases tied to protein misfolding. Its proprietary platforms generate biologics and small molecules targeting conditions like Alzheimer's disease and Parkinson's disease. The company maintains research collaborations with major pharmaceutical partners including Genentech, Janssen, and Eli Lilly.

What to Watch at ACIU

Market participants will monitor the company's next earnings report scheduled for November 4, 2026, for further updates on its clinical pipeline and financial status. Investors should remember that insider transaction reports filed under SEC rules reflect historical choices and do not guarantee future price directions.